July 2017 ENCALS statement on edaravone
Publication date
2017-11
Authors
Al-Chalabi, Ammar
Andersen, Peter M.
Chandran, Siddharthan
Chio, Adriano
Corcia, Philippe
Couratier, Philippe
Danielsson, Olof
de Carvalho, Mamede
Desnuelle, Claude
Grehl, Torsten
Editors
Advisors
Supervisors
Document Type
Article
Metadata
Show full item recordCollections
License
cc_by_nc_nd
Abstract
Keywords
Journal Article, Antipyrine/analogs & derivatives, Humans, Amyotrophic Lateral Sclerosis/drug therapy, Decision Making/physiology, Treatment Outcome, Free Radical Scavengers/therapeutic use, Edaravone, Clinical Neurology, Neurology, Journal Article, Review
Citation
Al-Chalabi, A, Andersen, P M, Chandran, S, Chio, A, Corcia, P, Couratier, P, Danielsson, O, de Carvalho, M, Desnuelle, C, Grehl, T, Grosskreutz, J, Holmøy, T, Ingre, C, Karlsborg, M, Kleveland, G, Christoph Koch, J, Koritnik, B, KuzmaKozakiewicz, M, Laaksovirta, H, Ludolph, A C, Mcdermott, C J, Meyer, T, Mitre Ropero, B, Mora Pardina, J, Nygren, I, Petri, S, Povedano Panades, M, Salachas, F, Shaw, P J, Silani, V, Staaf, G, Svenstrup, K, Talbot, K, Tysnes, O-B, Van Damme, P, van der Kooi, A J, Weber, M, Weydt, P, Wolf, J, Hardiman, O & van den Berg, L H 2017, 'July 2017 ENCALS statement on edaravone', Amyotrophic Lateral Sclerosis & Frontotemporal Degeneration, vol. 18, no. 7-8, pp. 471-474. https://doi.org/10.1080/21678421.2017.1369125